Cargando…
It can be dangerous to take epidemic curves of COVID-19 at face value
During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (avail...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309693/ https://www.ncbi.nlm.nih.gov/pubmed/32578184 http://dx.doi.org/10.17269/s41997-020-00367-6 |
_version_ | 1783549248031162368 |
---|---|
author | Burstyn, Igor Goldstein, Neal D. Gustafson, Paul |
author_facet | Burstyn, Igor Goldstein, Neal D. Gustafson, Paul |
author_sort | Burstyn, Igor |
collection | PubMed |
description | During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (available on 28 May 2020). There is presently no information of sensitivity (Sn) and specificity (Sp) of laboratory tests used in Canada for the causal agent for COVID-19. Therefore, we examined best attainable performance in other jurisdictions and similar viruses. This suggested perfect Sp and Sn 60–95%. We used these values to re-calculate epidemic curves to visualize the potential bias due to imperfect testing. If the sensitivity improved, the observed and adjusted epidemic curves likely fall within 95% confidence intervals of the observed counts. However, bias in shape and peak of the epidemic curves can be pronounced, if sensitivity either degrades or remains poor in the 60–70% range. These issues are minor early in the epidemic, but hundreds of undiagnosed cases are likely later on. It is therefore hazardous to judge progress of the epidemic based on observed epidemic curves unless quality of testing is better understood. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-020-00367-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7309693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73096932020-06-23 It can be dangerous to take epidemic curves of COVID-19 at face value Burstyn, Igor Goldstein, Neal D. Gustafson, Paul Can J Public Health Special Section on COVID-19: Commentary During an epidemic with a new virus, we depend on modelling to plan the response: but how good are the data? The aim of our work was to better understand the impact of misclassification errors in identification of true cases of COVID-19 on epidemic curves. Data originated from Alberta, Canada (available on 28 May 2020). There is presently no information of sensitivity (Sn) and specificity (Sp) of laboratory tests used in Canada for the causal agent for COVID-19. Therefore, we examined best attainable performance in other jurisdictions and similar viruses. This suggested perfect Sp and Sn 60–95%. We used these values to re-calculate epidemic curves to visualize the potential bias due to imperfect testing. If the sensitivity improved, the observed and adjusted epidemic curves likely fall within 95% confidence intervals of the observed counts. However, bias in shape and peak of the epidemic curves can be pronounced, if sensitivity either degrades or remains poor in the 60–70% range. These issues are minor early in the epidemic, but hundreds of undiagnosed cases are likely later on. It is therefore hazardous to judge progress of the epidemic based on observed epidemic curves unless quality of testing is better understood. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-020-00367-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-06-23 /pmc/articles/PMC7309693/ /pubmed/32578184 http://dx.doi.org/10.17269/s41997-020-00367-6 Text en © The Canadian Public Health Association 2020 |
spellingShingle | Special Section on COVID-19: Commentary Burstyn, Igor Goldstein, Neal D. Gustafson, Paul It can be dangerous to take epidemic curves of COVID-19 at face value |
title | It can be dangerous to take epidemic curves of COVID-19 at face value |
title_full | It can be dangerous to take epidemic curves of COVID-19 at face value |
title_fullStr | It can be dangerous to take epidemic curves of COVID-19 at face value |
title_full_unstemmed | It can be dangerous to take epidemic curves of COVID-19 at face value |
title_short | It can be dangerous to take epidemic curves of COVID-19 at face value |
title_sort | it can be dangerous to take epidemic curves of covid-19 at face value |
topic | Special Section on COVID-19: Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309693/ https://www.ncbi.nlm.nih.gov/pubmed/32578184 http://dx.doi.org/10.17269/s41997-020-00367-6 |
work_keys_str_mv | AT burstynigor itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue AT goldsteinneald itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue AT gustafsonpaul itcanbedangeroustotakeepidemiccurvesofcovid19atfacevalue |